Ingelheim, Germany / Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC were presented ...
Build a custom WordPress website in minutes with 10Web AI Builder. Intuitive, AI-powered, and perfect for non-tech users.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback